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ABSTRACT
The role of hematopoietic stem cell transplantation (SCT) in Waldenstrom’s macroglobulinemia (WM) has not
been extensively studied. To determine the potential for long-term disease control using SCT in WM, we
performed a retrospective review of 36 patients with WM who received autologous (n  10) or allogeneic (n
 26) SCT and were reported to the Center for International Blood and Marrow Transplant Research between
1986 and 2002. The following outcomes were described: nonrelapse mortality (NRM), relapse, progression-
free survival (PFS), and overall survival (OS). Median age at the time of SCT was 51 years (range, 30-76 years),
and median time from initial treatment to SCT was 29 months (range, 2-198 months). A total of 78% of the
patients had 2 or more previous chemotherapy regimens, and 52% had disease resistant to salvage chemo-
therapy. In the allogeneic SCT group, 58% of the patients received myeloablative conditioning regimens
containing total body irradiation (TBI), and of the allograft recipients, 19% received nonmyeloablative/
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A. Anagnostopoulos et al.846reduced-intensity conditioning. After a median follow-up of 65 months, 15 of the 36 patients (42%) are alive.
Primary disease accounted for 29% of the deaths in the allogeneic SCT group and 25% of the deaths in the
autologous SCT group. The relapse rate at 3 years was 29% (95% confidence interval [CI], 14%-48%) in the
allogeneic group and 24% (95% CI, 4%-54%) in the autologous group. PFS at 3 years was 31% (95% CI,
14%-50%) in the allogeneic group and 65% (95% CI, 32%-91%) in the autologous group; OS was 46% (95%
CI, 27%-65%) in the allogeneic group and 70% (95% CI, 40%-93%) in the autologous group. NRM at 3 years
was 40% (95% CI, 23%-59%) in the allogeneic group and 11% (95% CI, 0-36%) in the autologous group.
Autologous SCT is a safe and feasible treatment option for patients with WM, especially for those who present
with adverse prognostic factors. Allogeneic SCT carries a much higher (40%) risk of NRM and should not be
considered outside the context of a clinical trial.
© 2006 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Waldenstrom’s macroglobulinemia (WM) is a rare,
ow-grade lymphoplasmacytic malignancy of the elderly
ith an age-adjusted incidence rate of 1 person in
,000,000 and peak incidence beyond age 75 years [1].
he disease has a long natural history, and patients often
urvive more than 5 years after the initial diagnosis.
reatment is initiated when patients become symptom-
tic. The presence of systemic symptoms, bulky tumor
nﬁltration, amyloidosis, peripheral neuropathy, hyper-
iscocity, cold agglutinin anemia, and cytopenias are the
sual indications for treatment [2].
Current treatment options include alkylating
gents, nucleoside analogues, and rituximab. The
verall response rate for chlorambucil as a primary
reatment is about 50% [3]. The nucleoside analogues
udarabine and cladribine are associated with re-
ponse rates ranging from 40% to 90%, whereas the
ess toxic rituximab induces remission in about 1/3 of
reviously untreated patients [4]. Combination che-
otherapy regimens have been used with response
ates of 80% [5-10]. Despite high response rates to
hemotherapy, all patients eventually relapse. Rein-
uction of remission with alternative treatment is usu-
lly possible, but eventually resistance to all available
herapies develops [2]. In addition to increased age,
hich is adversely associated with survival in all stud-
es, other factors, including cytopenias, low serum albu-
in level, and high serum beta 2 microglobulin level, are
lso associated with shorter survival [6,11-17]. These
actors may not be predictive at the time of transplanta-
ion, however.
The role of hematopoietic stem cell transplanta-
ion (SCT), either autologous or allogeneic, in treat-
ng WM is not well established. SCT has generally
een used in refractory or high-risk WM patients;
owever, published experience is limited [18-27]. Be-
ause WM is compatible with prolonged survival in
ost patients, the role of SCT in treating WM and
hose prognostic features that identify patients most
ikely to beneﬁt from such aggressive treatment mo- calities need to be carefully deﬁned. Given the low
ncidence of WM and the absence of prospective stud-
es with SCT for WM, analysis of cumulative registry
ata remains the best available way to study the exist-
ng experience and the safety and efﬁcacy of SCT in
his disease.
The present study is a retrospective analysis of a
eries of patients who received autologous or alloge-
eic SCT for WM and were reported to the Center
or International Blood and Marrow Transplant Re-
earch (CIBMTR).
ATIENTS AND METHODS
ata Sources
The CIBMTR is a research afﬁliation of the In-
ernational Bone Marrow Transplant Registry
IBMTR), Autologous Blood and Marrow Transplant
egistry (ABMTR), and the National Marrow Donor
rogram (NMDP) comprising a voluntary working
roup of more than 450 transplantation centers
orldwide that contribute detailed data on consecu-
ive allogeneic and autologous hematopoietic SCTs to
Statistical Center at the Health Policy Institute of
he Medical College of Wisconsin in Milwaukee or
he NMDP Coordinating Center in Minneapolis.
articipating centers are required to report all trans-
lants consecutively; compliance is monitored by on-
ite audits. Patients are followed longitudinally, with
early follow-up. Computerized checks for errors,
hysician reviews of submitted data, and on-site audits
f participating centers ensure data quality. Observa-
ional studies conducted by the CIBMTR are done
ith a waiver of informed consent and in compliance
ith HIPAA regulations, as determined by the Insti-
utional Review Board and the Privacy Ofﬁcer of the
edical College of Wisconsin.
The CIBMTR collects data at 2 levels: registra-
ion and research. Registration data include disease
ype, age, sex, pretransplantation disease stage and
hemotherapy-responsiveness, date of diagnosis, graft
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Transplantation for Waldenstrom’s Macroglobulinemia 847ype (bone marrow-derived and/or blood-derived
tem cells), high-dose conditioning regimen, post-
ransplantation disease progression and survival, de-
elopment of a new malignancy, and cause of death.
equests for data on progression or death for regis-
ered patients are made at 6-month intervals. All
IBMTR teams contribute registration data. Re-
earch data are collected on subset of registered pa-
ients selected using a weighted randomization
cheme and include detailed disease and pretransplan-
ation and posttransplantation clinical information.
atients
Between 1986 and 2002, 57 patients underwent
CT (35 allogeneic and 22 autologous) for WM.
omprehensive patient, disease, and transplantation
haracteristics were available only for a subset of 36
atients who underwent transplantation in 24 trans-
lant centers in 7 countries. Patient, disease, and
ransplantation characteristics, as well as overall sur-
ival (OS) of those with or without comprehensive
ata were similar (OS at 3 years, 52% [95% conﬁ-
ence interval (CI), 36%-68%] vs 60% [95% CI,
8%-71%]; P  .44). Twenty-six patients underwent
llogeneic SCT, and 10 patients underwent autolo-
ous SCT. All patients fulﬁlled the diagnostic criteria
or WM as deﬁned by the Second International
orkshop on Waldenstrom’s Macroglobulinemia,
hat is, lymphoplasmacytoid inﬁltration of the bone
arrow and IgM monoclonal protein of any concen-
ration [28]. Demographics, disease characteristics at
he time of diagnosis and before transplantation, treat-
ent characteristics, and outcomes were analyzed. El-
gible cases came from 24 reporting teams from 7
ountries. Median follow-up of survivors was 65
onths (range, 24-103 months).
efinition of Response
Response criteria were deﬁned according to the
ecommendations from the Second International
orkshop on Waldenstrom’s Macroglobulinemia
29]. To be eligible for response (at least partial re-
ission [PR]), a minimum 50% reduction of serum
onoclonal IgM concentration and 50% improve-
ent in bulky adenopathy/organomegaly were re-
uired. Patients who achieved at least a PR with sal-
age chemotherapy before transplantation were
onsidered chemosensitive; those who did not achieve
t least a PR were considered chemoresistant.
ndpoints
The outcome parameters that we studied were
reatment-related or nonrelapse mortality (NRM), re-
apse, progression-free survival (PFS), and OS. NRM
as deﬁned as death from any cause within the ﬁrst 28
ays after transplantation or death thereafter in the bbsence of relapse or progression. Disease relapse or
rogression was deﬁned as a 25% increase in measur-
ble tumor mass lesions, bone marrow plasmacytosis,
r IgM serum concentration. PFS was deﬁned as the
ime from transplantation to relapse or death from any
ause. For analysis of OS, failure was death from any
ause; surviving patients were censored at the date of
ast contact.
tatistical Analyses
The probabilities of NRM and relapse were cal-
ulated using cumulative incidence rates to accommo-
ate competing risks; probabilities of PFS and OS
ere calculated using the Kaplan-Meier estimator
30,31]. Estimates of standard error for the survival
unction were calculated by Greenwood’s formula and
he 95% CI, using log-transformed intervals [32].
haracteristics of patients and assessment of potential
rognostic factors for survival were not statistically
nalyzed because of the small sample size. All compu-
ations were performed using SAS version 8.0 (SAS
nstitute, Cary, NC).
ESULTS
Patient and disease characteristics for the entire
tudy group and by SCT type are summarized in
able 1. Patient age at time of transplantation ranged
rom 30 to 76 years (median, 51 years). Among the
ntire study group, 53% of the patients (n  19) had
received or more previous lines of chemotherapy,
nd 68% had received nucleoside analogues as part of
revious therapy. The median time from primary
reatment to transplantation was 29 months (range,
-198 months), and 52% of the patients were resistant
o their most recent salvage chemotherapy. Only 33%
f the patients were in at least PR at the time of
ransplantation, whereas 25% of the patients were
rogressing or relapsing despite salvage chemother-
py. At the time of transplantation, 33% of the pa-
ients had a low serum albumin level (3g/dL), 14%
ad a high serum lactic dehydrogenase level, and 11%
ad a high serum beta 2 microglobulin level. Patients
n the allogeneic SCT group tended to be younger
nd were more likely to have splenic involvement and
rogressive disease. However, there were no statisti-
ally signiﬁcant differences in any parameter between
he 2 SCT groups. Median follow-up of survivors was
5 months (range, 24-103 months).
Seven of the 10 patients in the autologous SCT
roup received mobilized peripheral blood stem cells
4 mobilized with chemotherapy plus growth factors;
with growth factors alone), and the other 3 received
one marrow as the stem cell source. Among the 26
atients in the allogeneic SCT group, 13 received a
one marrow graft, 12 received a peripheral blood
TN
N
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A. Anagnostopoulos et al.848able 1. Characteristics of Patients who Underwent Transplantation for Waldenstrom’s Macroglobulinemia Reported to the CIBMTR, 1986-2002
Variable
All Patients Allogeneic Autologous
n Evaluable n (%) n Evaluable n (%) n Evaluable n (%)
umber of patients 36 26 10
umber of centers 24 19 7
atient-related
Age, median (range), years 36 51 (30-76) 26 49 (30-76) 10 56 (44-62)
Male 36 26 (72) 26 17 (65) 10 9 (90)
isease-related
Lactic dehyrogenase at diagnosis
>upper limit of normal 16 4 (25) 11 2 (18) 5 2 (40)
Albumin at diagnosis >3.5 g/dL 20 15 (75) 14 11 (79) 6 4 (67)
Hemoglobin at diagnosis <10g/dL 25 9 (36) 18 8 (44) 7 1 (14)
2-microglobulin at diagnosis >3.5 mg/L 10 2 (20) 6 1 (17) 4 1 (25)
Hyperviscosity at diagnosis 34 22 (65) 24 14 (58) 10 8 (80)
Previous chemotherapy regimens 36 26 10
Nucleoside analogues (2-CDA,
fludarabine) 25 (68) 18 (70) 7 (70)
CLB  others (not 2-CDA,
fludarabine) 5 (14) 5 (19) 0
ADM  others (not 2-CDA,
fludarabine, CLB) 2 (6) 1 (4) 1 (10)
Other 2 (6) 1 (4) 1 (10)
No chemotherapy regimen 2 (6) 1 (4) 1 (10)
Bone marrow infiltration at diagnosis, % 15 27 (2-100) 10 40 (10-100) 5 20 (2-50)
Number of lines of chemotherapy* 36 26 10
1 6 (17) 5 (19) 1 (10)
2 9 (25) 5 (19) 4 (40)
3 6 (17) 6 (23) 0
4 13 (36) 9 (35) 4 (40)
No chemotherapy 2 (5) 1 (4) 1 (10)
Sensitivity to chemotherapy before
SCT 35 25 10
Sensitive 12 (34) 7 (28) 5 (50)
Resistant 18 (52) 13 (52) 5 (50)
Not applicable† 5 (14) 5 (20) 0
Disease status before SCT 36 26 10
PR 12 (33) 7 (27) 5 (50)
Less than PR 14 (39) 10 (38) 4 (40)
Progressive/relapse 9 (25) 8 (31) 1 (10)
Not evaluable 1 (3) 1 (4) 0
Lactic dehydrogenase before SCT tx
>upper limit of normal 28 4 (14) 22 4 (18) 6 0
Albumin before SCT >3.5 g/dL 29 19 (66) 20 13 (65) 9 6 (67)
2-microglobulin before SCT >3.5 mg/L 18 2 (11) 13 1 (8) 5 1 (20)
ransplant-related
Time from diagnosis to SCT, median
(range), months 35 29 (2-198) 25 25 (2-198) 10 32 (9-114)
Donor 26 26 NA
HLA-identical sibling 20 (77) 20 (77)
Identical twin 1 (4) 1 (4)
Other relative 1 (4) 1 (4)
Unrelated donor 4 (15) 4 (15)
Mobilization treatment‡ 7 NA 7
Chemotherapy  growth factors 4 (57) 4 (57)
Growth factors 3 (43) 3 (43)
Conditioning regimen 36 26 10
TBI  other 18 (50) 15 (58) 3 (30)
BuCy  other 7 (19) 5 (19) 2 (20)
Fludarabine  other 1 (3) 1 (4) 0
NST 5 (14) 5 (19) 0
Other§ 5 (14) 0 5 (50)
Total number of nucleated cells infused,
8 10 /kg 29 4 (<1-164) 21 3 (<1-164) 8 11 (1-41)
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Transplantation for Waldenstrom’s Macroglobulinemia 849tem cell graft, and 1 received both (Table 1). Alloge-
eic SCT was performed most frequently (77%; 20
atients) from HLA-identical sibling donors; other
tem cell donors included 4 unrelated HLA-matched
onors, 1 identical twin, and 1 nonsibling relative.
he inclusion of syngeneic transplantation in the al-
ogeneic SCT group did not alter the median fol-
ow-up or the PFS or OS analysis. Graft-versus-host
isease prophylaxis varied based on the protocols used
t each center. A TBI-containing conditioning regi-
en was provided to 50% of the patients. The pa-
ients in the allogeneic SCT group were more likely to
eceive TBI conditioning than were those in the au-
ologous SCT group (58% vs 30%; P  .002). A
onmyeloablative conditioning regimen was provided
o 19% of the patients (n 5) who received allogeneic
CT.
Nine patients (25%) achieved complete remission
CR) at 100 days posttransplantation, 12 (33%) were
n PR, 4 (11%) were in less than PR, 1 (3%) had
able 1. Continued
Variable
All Patient
n Evaluable
Graft type 36
Bone marrow 16
PBSC 19
Bone marrow  PBSC 1
Year of transplantation 36
1986-1994 5
1995-1996 6
1997-1998 8
1999-2000 12
2001-2002 5
GVHD prophylaxis 26
CsA  other 4
MTXCsA  other 14
FK506  other 5
T-cell depletion 2
None (twin transplant) 1
Median FU of survivors, months 65
-CDA indicates 2-chloro-deoxyadenosine; ADM, adriamycin; BU,
FK506, tacrolimus; MTX, methotrexate; NA, not applicable; NS
total body irradiation; Completeness index, FU  89%, FU 
Excluding mobilization.
No chemotherapy or ended more than 6 months before condition
For autologous PBSC transplantations only.
Other conditioning regimens were cyclophosphamidearaceto
cyclophosphamide (1), and melphalan (2).
able 2. Response Rates at 100 days Posttransplantation by Disease Sta
aldenstrom’s Macroglobulinemia
Disease status
before SCT CR PR
Less than
PR
R 4 5 1
ess than PR 3 5 3
rogressive/relapse 2 2 0
ot evaluable 0 0 0rogressive disease, and 10 (28%) were not evaluable/
ad died at 100 days (Table 2). Table 2 shows that
esponse rates were similar regardless of the disease
tatus at time of transplantation. Overall NRM was
2% (95% CI, 18%-49%) for the entire group. NRM
as 40% (95% CI, 23%-59%) for the allogeneic SCT
roup and 11% (95% CI, 0-36%) for the autologous
CT group at both 1 year and 3 years. The overall risk
f progression was 15% (95% CI, 5%-28%) at 1 year,
ith 16% (95% CI, 5%-32%) for the allogeneic SCT
roup and 11% (95% CI, 0-36%) for the autologous
CT group, and 28% (95% CI, 14-44) at 3 years, with
9% (95% CI, 14%-48%) for the allogeneic SCT
roup and 24% (95% CI, 4%-54%) for the autolo-
ous SCT group (Table 3; Figures 1 and 2). PFS was
3% (95% CI, 36%-69%) at 1 year, with 44% (95%
I, 26%-63%) for the allogeneic group and 78%
95% CI, 47%-97%) for the autologous group, and
0% (95% CI, 14%-44%) at 3 years, with 31% (95%
I, 14%-50%) for the allogeneic group and 65%
Allogeneic Autologous
n Evaluable n (%) n Evaluable n (%)
26 10
13 (50) 3 (30)
12 (46) 7 (70)
1 (4) 0
26 10
3 (12) 2 (20)
5 (19) 1 (10)
3 (12) 5 (50)
10 (38) 2 (20)
5 (19) 0
26 NA
4 (15)
14 (54)
5 (19)
2 (8)
1 (4)
3) 75 (24-103) 63 (24-77)
n; CLB, chlorambucil; CSA, cyclosporine; CY, cyclophosphamide;
myeloablative transplant; PBSC, peripheral blood stem cells; TBI,
up.
nitrosourea (1), cyclophosphamideetoposidenitrosourea (1),
re SCT among Patients Who Underwent Transplantation for
Progressive/Relapse
Died at Less
than 100 days
Not
Evaluable
0 1 1
0 2 1
1 3 1s
n (%)
(44)
(53)
(3)
(14)
(17)
(22)
(33)
(14)
(15)
(54)
(19)
(8)
(4)
(24-10
busulfa
T, non
follow-
ing.
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A. Anagnostopoulos et al.85095% CI, 32%-91%) for the autologous group. OS
as 64% (95% CI, 48%-79%) at 1 year, with 58%
95% CI, 39%-76%) for the allogeneic group and
0% (95% CI, 51%-98%) for the autologous group,
nd 52% (95% CI, 36%-68%) at 3 years, with 46%
95% CI, 27%-65%) for the allogeneic group and
0% (95% CI, 40%-93%) for the autologous group
Table 3; Figures 3 and 4). After a median follow-up of
5 months (range, 24-103 months), 15 of the 36 pa-
ients (42%) are alive, 9 from the allogeneic SCT
roup (35%) and 6 (60%) from the autologous SCT
roup (Table 4). Primary disease was the cause of
eath in 6 patients (29% of deaths), whereas graft-
ersus-host disease and infection were the more com-
on causes of NRM, accounting for 3 (14%) and 5
24%) deaths, respectively. Organ failure, hemor-
hage, vascular events, and secondary malignancy
ere other causes of death.
able 3. Univariate Analysis among Patients Who Underwent SCT fo
All Patients
n
Evaluable
Probability
(95% CI)
RM* 34
At 1 year 32 (18-49)
At 3 years 32 (18-49)
elapse/progression* 34
At 1 year 15 (5-28)
At 3 years 28 (14-44)
FS* 34
At 1 year 53 (36-69)
At 3 years 40 (14-44)
S 36
At 1 year 64 (48-79)
At 3 years 52 (36-68)
Two patients were not evaluable (unknown relapse date).Figure 1. Cumulative incidence of NRM after SCT for WaldeISCUSSION
To the best of our knowledge, to date only 7 other
eries and a handful of case reports of patients with
his rare malignancy who received SCT have been
eported, accounting for a total of 25 allogeneic and
1 autologous SCTs [18-27]. Herein we report the
argest retrospective series in the literature, includ-
ng 36 patients receiving autologous (n  10) and
llogeneic (n  26) SCT. It is of interest that more
atients received allogeneic SCT than autologous
CT. This might be due to the fact that SCT was
iven as a salvage regimen mainly in heavily pre-
reated patients, in whom autologous grafting would
ot be a feasible option. It is possible that patients
ndergoing allogeneic SCT may have failed previous
ttempts at autologous stem cell collection. How-
ver, this hypothesis could not be tested within the
enstrom’s Macroglobulinemia
Allogeneic Autologous
n
luable
Probability
(95% CI)
n
Evaluable
Probability
(95% CI)
25 9
40 (23-59) 11 (0-36)
40 (23-59) 11 (0-36)
25 9
16 (5-32) 11 (0-36)
29 (14-48) 24 (4-54)
25 9
44 (26-63) 78 (47-97)
31 (14-50) 65 (32-91)
26 10
58 (39-76) 80 (51-98)
46 (27-65) 70 (40-93)r Wald
Evanstrom’s macroglobulinemia, by type of transplantation.
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Transplantation for Waldenstrom’s Macroglobulinemia 851vailable dataset. The relatively small number of
atients in our study limits our ability to analyze
hese data to draw statistically valid conclusions.
he low overall numbers are consistent with the
arity of patients with WM requiring transplanta-
ion in general.
Our cohort of patients had relatively good prog-
ostic factors at the time of initial treatment; only a
mall proportion had low albumin (25%) or high beta
microglobulin (20%) serum levels or anemia (Hb 
0g/dL in 36%) (Table 1). However, the relatively
ong median time from initial treatment to transplan-
ation (29 months), with the most of the patients
78%) undergoing 2 or more previous treatment reg-
mens, suggests that this is a heavily pretreated group
ith relatively poor prognosis. Moreover, approxi-
ately 50% of the patients had not achieved an ob-
ective response to salvage therapy before undergoing
CT. A 58% response rate (CR  PR) within the ﬁrst
Figure 2. Cumulative incidence of relapse mortality after SCTFigure 3. Probability of PFS after SCT for Waldenstrom00 days posttransplantation regardless of disease sta-
us before treatment (Table 2) suggests that SCT may
vercome drug resistance and induce a response in
atients who failed conventional treatment.
The autologous SCT group had a low NRM of
1% at 1 year and 3 years, demonstrating that autol-
gous SCT is safe for patients with WM. Moreover,
onsidering the fact that 8 of the 10 patients in the
utologous group had 2 or more previous treatment
egimens and only 5 of the 10 had sensitive disease at
ime of transplantation, the 65% long-term PFS and
0% OS are very encouraging results (Table 3; Fig-
res 3 and 4). In our series, the median age of the
atients who received autologous SCT was only 56
ears (range, 44-62 years), compared with the much
igher usual age at presentation of WM [1].
Autologous SCT may be a safe, feasible, and rea-
onable therapeutic option for younger WM patients
ith adverse prognosis. The feasibility and safety of
aldenstrom’s macroglobulinemia, by type of transplantation.’s macroglobulinemia, by type of transplantation.
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A. Anagnostopoulos et al.852igh-dose chemotherapy and autologous SCT in the
lderly is well established in myeloma and other set-
ings [19]. Therefore, although more evidence is
eeded, patient age may not necessarily preclude au-
ologous SCT to treat WM. Similarly, the position of
utologous SCT in the sequence of various therapies
vailable for treating WM remains to be determined.
ecently, Dreger et al [26] reported a series of 12 WM
atients who received autologous SCT after TBI and
igh-dose cyclophosphamide therapy as part of ﬁrst-
ine treatment and demonstrated no treatment-related
ortality and high response and survival rates. A care-
ul planning of the treatment strategy is indicated in
atients who are possible candidates for SCT. Har-
esting of autologous stem cells ideally should be done
efore nucleoside analogue exposure, because these
gents may impair stem cell collection [33-35], and
efore extensive bone marrow inﬁltration occurs.
In our allogeneic SCT subset, nonrelapse or trans-
lant mortality was high, with 40% of the patients
ying within 1 year after SCT due to causes unrelated
o their primary disease. This outcome is consistent
ith the other published series from France, in which
of the 10 patients who underwent allogeneic SCT to
Figure 4. Probability of OS after SCT for Walde
able 4. Causes of Death
All Patients
n Evaluable n (%)
umber of patients 36
umber of deaths 21
Primary disease 6 (29)
Graft-versus-host-disease 3 (14)
Infection 5 (24)
Organ failure 2 (10)
Hemorrhage 1 (5)
Vascular 2 (10)
New malignancy 1 (5)
Other 1 (5)reat WM died due to treatment-related reasons [25],
nd with other series involving allogeneic SCT for
ultiple myeloma [36]. Moreover, in our series, de-
pite the absence of further NRM beyond 1 year,
elapse/progression continued to occur beyond 12
onths after transplantation. This ﬁnding argues
gainst the existence of a strong immune-mediated
raft-versus-tumor effect. However, 21 of the 26 pa-
ients received a potentially more toxic myeloablative
reparative regimen. Further clinical studies with new
ethodologies, such as nonmyeloablative SCT, may
e associated with lower NRM rates, as described in
ther series [24,26].
Most patients with WM are of advanced age at
ime of presentation. Historically, SCT is a treatment
eserved for younger patients without major comor-
idities. However, advances in supportive care and the
se of peripheral blood as a stem cell source have
xtended the use of this treatment modality to patients
ith concurrent medical conditions and/or of ad-
anced age [37-39]. This study increases the published
xperience on SCT for WM and conﬁrms the fact that
utologous SCT is a reasonable treatment option (de-
pite the small patient cohort studied). Myeloablative
’s macroglobulinemia, by type of transplantation.
Allogeneic Autologous
n Evaluable n (%) n Evaluable n (%)
26 10
17 4
5 (29) 1 (25)
3 (18) 0
4 (24) 1 (25)
2 (12) 0
1 (6) 0
1 (6) 1 (25)
0 1 (25)
1 (6) 0
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Transplantation for Waldenstrom’s Macroglobulinemia 853llogeneic SCT in WM is feasible but associated with
igh treatment-related mortality. Both of these treat-
ent modalities merit further investigation in clinical
rials for both upfront and salvage therapies in risk-
ppropriate patients.
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